Immune Rebound: Multiple Sclerosis after Treatment of Cushing’s disease

Authors

  • Peyman Petramfar Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:

High cortisol level in endogenous Cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after treatment of Cushing’s syndrome. A 42-year old man is reported who presented with bone fracture and osteoporosis and diagnosed with Cushing’s disease. Six months after surgical treatment of his pituitary adenoma, he developed progressive multiple sclerosis. We conclude that after treatment of endogenous Cushing’s syndrome, the patients should be watched for development of autoimmune disorders including those affecting the central nervous system.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

immune rebound: multiple sclerosis after treatment of cushing’s disease

high cortisol level in endogenous cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. this is the second reported case of multiple sclerosis developing after treatment of cushing’s syndrome. a 42-year old man is reported who presented with bone fracture and...

full text

Immune Rebound: Multiple Sclerosis after Treatment of Cushing's Disease.

High cortisol level in endogenous Cushing's syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after treatment of Cushing's syndrome. A 42-year old man is reported who presented with bone fracture and...

full text

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis

Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time.   Case Report: Here, we introduce a young girl, a known case of MS, who developed revers...

full text

Immune competence after alemtuzumab treatment of multiple sclerosis.

OBJECTIVE To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. METHODS In this pilot case-control study, we assessed immunocompetence in 24 patients after alemtuzumab treatment by measuring antibody responses to 3 vaccines (diphtheria, tetanus, and poliomyelitis vaccine, Haemophilus influenzae type b ...

full text

Graves' disease after treatment with alemtuzumab for multiple sclerosis.

CONTEXT Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders. SETTING Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center. PATIENTS Fiv...

full text

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

BACKGROUND The oral sphingosine-1-phosphate receptor modulator fingolimod (FTY720) was recently approved for the treatment of relapsing-remitting multiple sclerosis. To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce. OBJECTIVE To describe a patient who discontinued fingolimod treatment after a local malignant melanoma was di...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 13  issue 1

pages  64- 68

publication date 2016-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023